Table 2.
Results of cost-effectiveness analysis
| Transmission setting | Low to moderate | Moderate to high |
|---|---|---|
| Mean (95% CI) | Mean (95% CI) | |
| Uncomplicated malaria episodes: DP treatment | 3.1 (2.7–3.5) | 3.9 (3.2–4.6) |
| Uncomplicated malaria episodes: AL treatment | 3.3 (2.9–3.8) | 4.8 (4.0–5.6) |
| Uncomplicated malaria episodes averted | 0.22 (0.17–0.27) | 0.86 (0.47–1.31) |
| Severe malaria episodes averted | 0.004 (−0.003 to 0.014) | 0.015 (−0.001 to 0.047) |
| Incremental costs | 0.07 (−1.07 to 1.12) | −1.09 (−3.85 to 0.88) |
| DALYs averted | 0.01 (−0.05 to 0.09) | 0.05 (−0.08 to 0.22) |
| ICER (US$ per DALY averted) | 5 (−76 to 196) | Dominant strategy |
AL = artemether–lumefantrine; CI = confidence interval; DALYs = disability-adjusted life years; DP = dihydroartemisinin–piperaquine; ICER = incremental cost-effectiveness ratio.
All values are calculated per child over 1 year and all costs are in U.S. dollars for the year 2013.